About Us 

Blackhawk Science Inc. is a science-driven licensing company that holds an exclusive license to a patent-pending formulation that when combined with orally taken Cannabidiol (CBD) protects the liver from the toxic damage caused by traditional ways of creating CBD products. 

The Blackhawk Difference

The FDA has expressed concerns over potential damage to the liver when consuming CBD’s in oral supplements.

Blackhawk Science inc. hold a license for a formulation (patent pending) which, when combined with orally taken CBD’s, protects the liver from damage. 

Company Prospectus

The marketplace for the use of orally administered CBD’s has grown exponentially over the last few years and continues to exhibit huge growth potential. The market is expected to reach over 2 Billion Dollars in sales in North America in the coming year with a projected compound annual growth rate of 32% to 2024, with health benefits of CBD oil being one of the major drivers of the market.

Contact us

Please enable JavaScript in your browser to complete this form.
Name